sentence_eng_Latn: “The EU approval of Perjeta is the result of years of research into the HER2 pathway and we are excited to offer a new treatment option for people with this aggressive disease,” said Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development. “The combination of Perjeta, Herceptin
sentence_ayr_Latn: “UE ukan Perjeta walikiw satax HER2 ukanam ukxat walja maranak yatxatatat jikxatatawa ukat sintt’ayir usun jaqinakatak mä machaq uñjañ utjatapat kusisitäpxtwa”, saw Hal Barron, MD, qullañ irpiri ukat uraqpachan yänak lurañ p’iqinchiri jupax sawayi. Perjeta, Herceptin tinkt’ayata